 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Clinical-stage psychedelics biotech Reunion Neuroscience (NASDAQ: REUN) and MPM BioImpact have completed their announced plan of arrangement for MPM&rsq
read more...

Reunion Neuroscience Completes Take-Private Setup: Delisting & Consideration Details

TORONTO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions and MPM BioImpact ("...

Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement

TORONTO, July 14, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions is pleased to ...

Reunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of Arrangement

TORONTO, July 13, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the Company), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, is pleased to announce...

Reunion Neuroscience Inc. Shareholders Approve Proposed Plan of Arrangement

Common Shareholders to Receive Consideration of US$1.12 Per Share in Cash from the Arrangement Agreement with MPM BioImpact; Special Shareholder Meeting Scheduled July 12 Presented Encouraging Phase 1 Final Analysis at American Society of Clinical Psychopharmacology Annual Meeting TORONTO, June 29, ...

Reunion Neuroscience Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Clinical-stage psychedelics firm Reunion Neuroscience Inc. (NASDAQ: REUN) reported fiscal results for the fourth quarter and year ended March 31 plus corporate updates.
Here's a breakdown of the report:
read more...

Reunion Neuroscience's Q4 And Full Year 2023 Financial Results, To Close Take-Private Deal In Q3

Avidity Partners Management LP lessened its holdings in Reunion Neuroscience Inc. (NASDAQ:REUN  Get Rating) by 5.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 560,300 shares of the companys stock ...

Avidity Partners Management LP Has $504,000 Stock Position in Reunion Neuroscience Inc. (NASDAQ:REUN)

NEW YORK, June 14, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the M&A Class Action Firm), a national securities firm ratedTop 50in the 2018-2021 ISS Securities Class Action Services Report and headquartered at theEmpire...

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - REUN, ARNC, PTRS, FOCS

Reunion Neuroscience (NASDAQ:REUN Get Rating) and aTyr Pharma (NASDAQ:LIFE Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, profitability, analyst...

Reviewing Reunion Neuroscience (NASDAQ:REUN) and aTyr Pharma (NASDAQ:LIFE)

Reunion Neuroscience (NASDAQ:REUN  Get Rating) and aTyr Pharma (NASDAQ:LIFE  Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, ...

Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada.

Watchers	223
52-Wk Low	$0.6303
52-Wk High	$22.00

Market Cap	$16.64M
Volume (M)	17.00
52-Wk High	$22.00
52-Wk Low	$0.6303

REUN Reunion Neuroscience Inc

About

Feed

News

Earnings

Fundamentals